Kelly Deck - May 30, 2024 Form 4 Insider Report for Inhibrx Biosciences, Inc. (INXB)

Role
Chief Financial Officer
Signature
/s/ Kelly D. Deck
Stock symbol
INXB
Transactions as of
May 30, 2024
Transactions value $
$0
Form type
4
Date filed
5/30/2024, 06:09 PM
Previous filing
May 24, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INXB Stock Option (right to buy) Award $0 +175K $0.00 175K May 30, 2024 Common Stock 175K $15.86 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi.
F2 Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on May 30, 2025, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.